Immunohistochemistry and renal neoplasias

1.   Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC; 2016.

2.   Wasco MJ, Pu RT. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration. Diagn Cytopathol 2008; 36(8): 568-573.

3.   Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol 2011; 35(12): 1837-1847.

4.   Gokden N, Gokden M, Phan DC, McKenney JK. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008; 32(10): 1462-1467.

5.   Reuter VE, Argani P, Zhou M, Delahunt B, Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014; 38(8): e35-49.

6.   Sangoi AR, Karamchandani J, Kim J, Pai RK, McKenney JK. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol 2010; 17(6): 377-393.

7.   Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011; 35(6): 816-826.

8.   Cox RM, Magi-Galluzzi C, McKenney JK. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update. Advances in anatomic pathology. 2018;25(6):387-99.

9.   McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody ‘Renal Cell Carcinoma Marker’. Am J Surg Pathol 2001; 25(12): 1485-1492.

10. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10(6): 537-544.

11. Langner C, Wegscheider BJ, Ratschek M, Schips L, Zigeuner R. Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Arch 2004; 444(2): 127-134.

12. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998; 153(5): 1467-1473.

13. Kovac M, Navas C, Horswell S, et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun 2015; 6: 6336.

14. Yu W, Zhang W, Jiang Y, et al. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information. Acta Histochem 2013; 115(5): 452-459.

15. Marsaud A, Dadone B, Ambrosetti D, et al. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases. Genes Chromosomes Cancer 2015; 54(6): 369-382.

16. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003; 63(19): 6200-6205.

17. Antonelli A, Tardanico R, Balzarini P, et al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet  2010; 199(2): 128-133.

18. Saleeb RM, Brimo F, Farag M, et al. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. Am J Surg Pathol 2017; 41(12): 1618-1629.

19. Pitra T, Pivovarcikova K, Alaghehbandan R, Hes O. Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. Ann Diagn Pathol 2019; 40: 189-199.

20. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007; 31(10): 1578-1585.

21. Muller M, Guillaud-Bataille M, Salleron J, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol 2018; 31(6): 974-983.

22. Smith SC, Trpkov K, Chen YB, et al. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol 2016; 40(11): 1457-1472.

23. Ulamec M, Skenderi F, Zhou M, et al. Molecular Genetic Alterations in Renal Cell Carcinomas With Tubulocystic Pattern: Tubulocystic Renal Cell Carcinoma, Tubulocystic Renal Cell Carcinoma With Heterogenous Component and Familial Leiomyomatosis-associated Renal Cell Carcinoma. Clinicopathologic and Molecular Genetic Analysis of 15 Cases. Appl Immunohistochem Mol Morphol 2016; 24(7): 521-530.

24. Trpkov K, Hes O, Agaimy A, et al. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. Am J Surg Pathol 2016; 40(7): 865-875.

25. Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology 2018; 72(4): 588-600.

26. Pivovarčíková K, Martínek P, Trpkov K, et al. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases. Cesk Patol 2019; 55(4): 244–249.

27. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98(6): 3387-3392.

28. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30(4): 406-410.

29. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73(1): 95-106.

30. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43(1): 18-27.

31. Bardella C, El-Bahrawy M, Frizzell N, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011; 225(1): 4-11.

32. Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 2014; 38(5): 627-637.

33. Kuroda N, Ohe C, Kawakami F, et al. Clear cell papillary renal cell carcinoma: a review. Int J Clin Exp Pathol 2014; 7(11): 7312-7318.

34. Aron M, Chang E, Herrera L, et al. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor. Am J Surg Pathol 2015; 39(7): 873-888.

35. Deml KF, Schildhaus HU, Comperat E, et al. Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol 2015; 39(7): 889-901.

36. Hes O, Comperat EM, Rioux-Leclercq N. Clear cell papillary renal cell carcinoma, renal angiomyoadenomatous tumor, and renal cell carcinoma with leiomyomatous stroma relationship of 3 types of renal tumors: a review. Ann Diagn Pathol 2016; 21: 59-64.

37. Argani P, Zhong M, Reuter VE, et al. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 2016; 40(6): 723-737.

38. Argani P, Zhang L, Reuter VE, Tickoo SK, Antonescu CR. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol 2017; 41(5): 655-662.

39. Xia QY, Wang XT, Zhan XM, et al. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3. Am J Surg Pathol 2017; 41(5): 663-676.

40. Wang XT, Xia QY, Ni H, et al. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion. Hum Pathol 2017; 63: 190-200.

41. Hayes M, Peckova K, Martinek P, et al. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma. Virchows Arch 2015; 466(3): 313-322.

42. Udager AM, Pan J, Magers MJ, et al. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol 2015; 39(4): 549-557.

43. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma. Mod Pathol 2003; 16(10): 1060-1063.

44. Gonzalez ML, Alaghehbandan R, Pivovarcikova K, et al. Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells. Histopathology 2019; 74(4): 608-617.

45. Williamson SR, Halat S, Eble JN, et al. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol 2012; 36(10): 1425-1433.

46. Parilla M, Alikhan M, Al-Kawaaz M, et al. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma. Am J Surg Pathol 2019; 43(8): 1135-1144.

47. Trpkov K, Hes O. New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology 2019; 74(1): 31-59.

48. Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med 2012; 136(4): 391-399.

49. Fuzesi L, Gunawan B, Bergmann F, Tack S, Braun S, Jakse G. Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3p. Histopathology 1999; 35(2): 157-161.

50. Salama ME, Worsham MJ, DePeralta-Venturina M. Malignant papillary renal tumors with extensive clear cell change: a molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch Pathol Lab Med 2003; 127(9): 1176-181.

51. Jia L, Jayakumaran G, Al-Ahmadie H, et al. USCAP 2018 Abstracts: Clear cell renal cell carcinoma with prominent papillary architecture: a rare morphologic variant supported by molecular evidence. Mod Pathol 2018; 31: 323.

52. Alaghehbandan R, Ulamec M, Martinek P, et al. Papillary pattern in clear cell renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases. Ann Diagn Pathol 2019; 38: 80-86.

53. Trpkov K, Williamson SR, Gao Y, et al. Low-grade Oncocytic Tumor of Kidney (CD117 Negative, Cytokeratin 7 Positive): A Distinct Entity? Histopathology 2019; 75(2): 174-184.

54. He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch 2018; 473(6): 725-738.

55. Trpkov K, Bonert M, Gao Y, et al. High-grade Oncocytic Tumor (HOT) of Kidney in a Patient with Tuberous Sclerosis Complex. Histopathology 2019; 75(3): 440-442.

56. Xia QY, Rao Q, Shen Q, et al. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol 2013; 6(7): 1392-1399.

57. Hes O, Brunelli M, Michal M, et al. Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol 2006; 10(3): 133-139.

58. Park BH, Ro JY, Park WS, et al. Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course. Pathol Int 2009; 59(3): 137-146.

59. Lefevre M, Couturier J, Sibony M, et al. Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol 2005; 29(12): 1576-1581.

60. Han G, Yu W, Chu J, et al. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases. Pathol Res Pract 2017; 213(1): 1-6.

61. Kunju LP, Wojno K, Wolf JS, Jr., Cheng L, Shah RB. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 2008; 39(1): 96-101.

62. Michalova K, Steiner P, Montiel DP, et al. Chromosomal Aberration Pattern in Oncocytic Papillary Renal Cell Carcinoma: Analysis of 28 Cases.  United States & Canadian Academy of Pathology 106th Annual Meeting; San Antonio: Mod Pathol 2017; p. 243 A.

63. Michalova K, Steiner P, Alaghehbandan R, et al. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases. Ann Diagn Pathol 2018; 35: 1-6.

64. Tickoo SK, Amin MB, Linden MD, Lee MW, Zarbo RJ. Antimitochondrial antibody (113-1) in the differential diagnosis of granular renal cell tumors. Am J Surg Pathol 1997; 21(8): 922-930.

65. Hes O, Michal M, Boudova L, Mukensnabl P, Kinkor Z, Miculka P. Small cell variant of renal oncocytoma--a rare and misleading type of benign renal tumor. Int J Surg Pathol 2001; 9(3): 215-222.

66. Zhang W, Yu W, Wang Q, Jiang Y, Li Y. The clinicopathological, ultrastructural, genetic features and diagnosis of small cell variant renal oncocytoma. Acta Histochem 2015; 117(6): 505-511.

67. Rocca PC, Brunelli M, Gobbo S, et al. Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. Mod Pathol 2007; 20(7): 722-728.

68. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005; 29(6): 747-754.

69. Mathers ME, Pollock AM, Marsh C, O’Donnell M. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology 2002; 40(6): 563-567.

70. Hes O, Michal M, Kuroda N, et al. Vimentin reactivity in renal oncocytoma: immunohistochemical study of 234 cases. Arch Pathol Lab Med 2007; 131(12): 1782-1788.

71. Wobker SE, Williamson SR. Modern Pathologic Diagnosis of Renal Oncocytoma. J Kidney Cancer VHL 2017; 4(4): 1-12.

72. Fuzesi L, Frank D, Nguyen C, Ringert RH, Bartels H, Gunawan B. Losses of 1p and chromosome 14 in renal oncocytomas. Cancer Genet Cytogenet 2005; 160(2): 120-125.

73. Joshi S, Tolkunov D, Aviv H, et al. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep 2015; 13(9): 1895-1908.

74. Anderson CB, Lipsky M, Nandula SV, et al. Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes Chromosomes Cancer 2019; doi: 10.1002/gcc.22766. [Epub ahead of print]

75. Michal M, Hes O, Svec A, Ludvikova M. Pigmented microcystic chromophobe cell carcinoma: a unique variant of renal cell carcinoma. Ann Diagn Pathol 1998; 2(3): 149-153.

76. Dundr P, Pesl M, Povysil C, et al. Pigmented microcystic chromophobe renal cell carcinoma. Pathol Res Pract 2007; 203(8): 593-597.

77. Kuroda N, Tanaka A, Yamaguchi T, et al. Chromophobe renal cell carcinoma, oncocytic variant: a proposal of a new variant giving a critical diagnostic pitfall in diagnosing renal oncocytic tumors. Med Mol Morphol 2013; 46(1): 49-55.

78. Hes O, Vanecek T, Perez-Montiel DM, et al. Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation--a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases. Virchows Arch 2005; 446(4): 383-393.

79. Kuroda N, Iiyama T, Moriki T, Shuin T, Enzan H. Chromophobe renal cell carcinoma with focal papillary configuration, nuclear basaloid arrangement and stromal osseous metaplasia containing fatty bone marrow element. Histopathology 2005; 46(6): 712-713.

80. Parada DD, Pena KB. Chromophobe renal cell carcinoma with neuroendocrine differentiation. APMIS 2008; 116(9): 859-865.

81. Kuroda N, Tamura M, Hes O, Michal M, Gatalica Z. Chromophobe renal cell carcinoma with neuroendocrine differentiation and sarcomatoid change. Pathol Int 2011; 61(9): 552-554.

82. Foix MP, Dunatov A, Martinek P, et al. Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant. Virchows Arch 2016; 469(6): 669-678.

83. Gutierrez FJQ, Panizo A, Tienza A, et al. Cytogenetic and immunohistochemical study of 42 pigmented microcystic chromophobe renal cell carcinoma (PMChRCC). Virchows Arch 2018; 473(2): 209-217.

84. Williamson SR, Gadde R, Trpkov K, et al. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol 2017; 63: 149-156.

85. Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 2005; 18(2): 161-169.

86. Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 1992; 4(3): 267-268.

87. Sperga M, Martinek P, Vanecek T, et al. Chromophobe renal cell carcinoma--chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases. Virchows Arch 2013; 463(4): 563-573.

88. Brunelli M, Gobbo S, Cossu-Rocca P, et al. Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Mod Pathol 2007; 20(3): 303-309.

89. Trpkov K, Hes O, Bonert M, et al. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women. Am J Surg Pathol 2016; 40(1): 60-71.

90. Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity. Am J Surg Pathol 2017; 41(10): 1299-1308.

91. McKenney JK, Przybycin CG, Trpkov K, Magi-Galluzzi C. Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. Histopathology 2018; 72(6): 1066-1067.

92. Argani P. A Molecular Marker for Eosinophilic Solid and Cystic Renal Cell Carcinoma. Eur Urol 2018; 74(4): 487-488.

93. Mehra R, Vats P, Cao X, et al. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. Eur Urol 2018; 74(4): 483-486.

94. Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum. Am J Surg Pathol 2018; 42(9): 1166-1181.

95. Parilla M, Kadri S, Patil SA, et al. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? Am J Surg Pathol 2018; 42(7): 911-917.

96. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014; 38(12): 1588-1602.

97. Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 2015; 28(1): 80-94.

98. Peckova K, Vanecek T, Martinek P, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol 2014; 18(6): 351-357.

99. Gupta S, Johnson SH, Vasmatzis G, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol 2017; 30(7): 998-1012.

100. Williamson SR, Grignon DJ, Cheng L, et al. Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis? Am J Surg Pathol 2017; 41(3): 287-298.

101. Ruiz-Cordero R, Rao P, Li L, et al. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol 2019; doi: 10.1038/s41379-019-0304-y. [Epub ahead of print].

102. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 2010; 456(4): 355-365.

103. Pote N, Vieillefond A, Couturier J, et al. Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas. Virchows Arch 2013; 462(6): 633-638.

104. Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm. Am J Surg Pathol 2019; 43(1): 121-131.

105. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol 2009; 22(9): 1218-1227.

106. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014; 38(1): 13-22.

107. Mantilla JG, Antic T, Tretiakova M. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics. Hum Pathol 2017; 66: 152-158.